{"id":57082,"date":"2025-09-23T07:01:52","date_gmt":"2025-09-23T07:01:52","guid":{"rendered":"https:\/\/prosfunds.com\/?p=57082"},"modified":"2025-09-23T07:01:53","modified_gmt":"2025-09-23T07:01:53","slug":"ars-pharmaceuticals-a-significant-upside-is-expected-from-neffy-nasdaqspry","status":"publish","type":"post","link":"https:\/\/prosfunds.com\/?p=57082","title":{"rendered":"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY)"},"content":{"rendered":"<div data-test-id=\"author-root\">\n<p class=\"mb-12 text-medium-2-r text-share-text-3\">This article was written by<\/p>\n<div class=\"relative mb-12 flex justify-between\">\n<div class=\"flex\">\n<div class=\"flex shrink-0 items-center justify-center relative size-36 rounded-full\" data-test-id=\"user-pic-wrapper\"><\/div>\n<\/div>\n<p><button data-state-text=\"Following\" aria-label=\"Follow Fundamental Options\" class=\"ihjjQ py-8 px-18 o7ZP8 ml-8 mt-0 shrink-0 self-baseline text-small-b relative inline-flex cursor-pointer select-none items-center whitespace-nowrap break-words transition-colors hover:no-underline motion-reduce:transition-none border-black bg-black text-white hover:bg-black-70 disabled:border-transparent disabled:bg-black-20 dark:border-black-10 dark:bg-black-10 dark:text-black dark:hover:border-black-30 dark:hover:bg-black-30 dark:disabled:bg-black-30 w-auto min-h-28 justify-center border px-12 py-1 text-medium-r rounded-6\" data-test-id=\"follow-button\" type=\"button\"><span class=\"\"><span aria-hidden=\"true\" class=\"wMAFB relative flex justify-center\" data-state-placeholder=\"Following\"><span class=\"absolute\">Follow<\/span><\/span><\/span><\/button><\/p>\n<\/div>\n<div class=\"text-medium-2-r\">\n<div class=\"relative\">\n<div class=\"relative overflow-hidden\" style=\"max-height:100%\">\n<div>\n<p>&#8220;Fundamental Options&#8221; would be the title of my investing style, because I combine fundamental analysis with the power of options. I use Fundamental Analysis to quantitatively and qualitatively assess individual stocks and ETFs, and I pursue various strategies: Income oriented, especially BDCs, but also Utilities; Growth At A Reasonable Price, especially Tech, having a background in Software Development; Deep Value, based on Discounted Cash Flow and \/ or other industry specific valuation methods; Dividend Aristocrats.While I usually invest in stocks for long-term, I also have 20-25 strategies involving options that I use for various purposes: hedging stocks; bullish stock \/ ETF substitutes with improved risk \/ reward; neutral trades; trading volatility; earnings-related trades.Teaching is another passion of mine, I used to be a formal on non-formal teacher or coach in different areas of life, including authoring of a free local investing newsletter in the last years.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div data-test-id=\"content-container\">\n<p id=\"a-disclosure\"><b>Analyst\u2019s Disclosure:<\/b><span>I\/we have a beneficial long position in the shares of SPRY either through stock ownership, options, or other derivatives.<\/span><span id=\"top-business-disclosure\"> I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. <\/span><\/p>\n<p>I have a covered Call position in SPRY.<\/p>\n<p id=\"a-disclosure-more\"><strong>Seeking Alpha&#8217;s Disclosure:<\/strong> Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.<\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/seekingalpha.com\/article\/4825008-ars-pharmaceuticals-stock-significant-upside-expected-from-neffy-reiterate-buy?source=feed_all_articles\" target=\"_blank\" rel=\"noopener\" rel=\"nofollow\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This article was written by Follow &#8220;Fundamental Options&#8221; would be the title of my investing style, because I combine fundamental analysis with the power of options. I use Fundamental Analysis to quantitatively and qualitatively assess individual stocks and ETFs, and I pursue various strategies: Income oriented, especially BDCs, but also Utilities; Growth At A Reasonable [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":57083,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[38],"tags":[],"class_list":{"0":"post-57082","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY) | Prosfunds<\/title>\n<meta name=\"description\" content=\"This article was written byFollow&quot;Fundamental Options&quot; would be the title of my investing style, because I combine fundamental analysis with the power of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prosfunds.com\/?p=57082\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY) | Prosfunds\" \/>\n<meta property=\"og:description\" content=\"This article was written byFollow&quot;Fundamental Options&quot; would be the title of my investing style, because I combine fundamental analysis with the power of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prosfunds.com\/?p=57082\" \/>\n<meta property=\"og:site_name\" content=\"Prosfunds\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T07:01:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T07:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prosfunds.com\/wp-content\/uploads\/2025\/09\/image_1781865454.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1014\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/prosfunds.com\/?p=57082#article\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/?p=57082\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\"},\"headline\":\"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY)\",\"datePublished\":\"2025-09-23T07:01:52+00:00\",\"dateModified\":\"2025-09-23T07:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/prosfunds.com\/?p=57082\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/prosfunds.com\/?p=57082#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/prosfunds.com\/?p=57082\",\"url\":\"https:\/\/prosfunds.com\/?p=57082\",\"name\":\"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY) | Prosfunds\",\"isPartOf\":{\"@id\":\"https:\/\/prosfunds.com\/#website\"},\"datePublished\":\"2025-09-23T07:01:52+00:00\",\"dateModified\":\"2025-09-23T07:01:53+00:00\",\"description\":\"This article was written byFollow\\\"Fundamental Options\\\" would be the title of my investing style, because I combine fundamental analysis with the power of\",\"breadcrumb\":{\"@id\":\"https:\/\/prosfunds.com\/?p=57082#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/prosfunds.com\/?p=57082\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/prosfunds.com\/?p=57082#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/prosfunds.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/prosfunds.com\/#website\",\"url\":\"https:\/\/prosfunds.com\/\",\"name\":\"Funding Factories\",\"description\":\"Latest Finance News and Updates\",\"publisher\":{\"@id\":\"https:\/\/prosfunds.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/prosfunds.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/prosfunds.com\/#organization\",\"name\":\"Funding Factories\",\"url\":\"https:\/\/prosfunds.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png\",\"width\":780,\"height\":140,\"caption\":\"Funding Factories\"},\"image\":{\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/prosfunds.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"contentUrl\":\"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/prosfunds.com\"],\"url\":\"https:\/\/prosfunds.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY) | Prosfunds","description":"This article was written byFollow\"Fundamental Options\" would be the title of my investing style, because I combine fundamental analysis with the power of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prosfunds.com\/?p=57082","og_locale":"en_US","og_type":"article","og_title":"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY) | Prosfunds","og_description":"This article was written byFollow\"Fundamental Options\" would be the title of my investing style, because I combine fundamental analysis with the power of","og_url":"https:\/\/prosfunds.com\/?p=57082","og_site_name":"Prosfunds","article_published_time":"2025-09-23T07:01:52+00:00","article_modified_time":"2025-09-23T07:01:53+00:00","og_image":[{"width":1536,"height":1014,"url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2025\/09\/image_1781865454.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prosfunds.com\/?p=57082#article","isPartOf":{"@id":"https:\/\/prosfunds.com\/?p=57082"},"author":{"name":"News Room","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6"},"headline":"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY)","datePublished":"2025-09-23T07:01:52+00:00","dateModified":"2025-09-23T07:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/prosfunds.com\/?p=57082"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prosfunds.com\/?p=57082#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prosfunds.com\/?p=57082","url":"https:\/\/prosfunds.com\/?p=57082","name":"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY) | Prosfunds","isPartOf":{"@id":"https:\/\/prosfunds.com\/#website"},"datePublished":"2025-09-23T07:01:52+00:00","dateModified":"2025-09-23T07:01:53+00:00","description":"This article was written byFollow\"Fundamental Options\" would be the title of my investing style, because I combine fundamental analysis with the power of","breadcrumb":{"@id":"https:\/\/prosfunds.com\/?p=57082#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prosfunds.com\/?p=57082"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prosfunds.com\/?p=57082#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prosfunds.com\/"},{"@type":"ListItem","position":2,"name":"ARS Pharmaceuticals: A Significant Upside Is Expected From neffy (NASDAQ:SPRY)"}]},{"@type":"WebSite","@id":"https:\/\/prosfunds.com\/#website","url":"https:\/\/prosfunds.com\/","name":"Funding Factories","description":"Latest Finance News and Updates","publisher":{"@id":"https:\/\/prosfunds.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prosfunds.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/prosfunds.com\/#organization","name":"Funding Factories","url":"https:\/\/prosfunds.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/ff-dark-logo-1.png","width":780,"height":140,"caption":"Funding Factories"},"image":{"@id":"https:\/\/prosfunds.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/bab8f1b00ccebe43e39ff640793108e6","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/prosfunds.com\/#\/schema\/person\/image\/","url":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","contentUrl":"https:\/\/prosfunds.com\/wp-content\/uploads\/2023\/08\/avatar_user_1_1693518183-96x96.png","caption":"News Room"},"sameAs":["https:\/\/prosfunds.com"],"url":"https:\/\/prosfunds.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/57082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57082"}],"version-history":[{"count":1,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/57082\/revisions"}],"predecessor-version":[{"id":57084,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/posts\/57082\/revisions\/57084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=\/wp\/v2\/media\/57083"}],"wp:attachment":[{"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prosfunds.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}